Parallax AHA Edition: 3 Trials that will change your practice with Dr Amit Khera
In this AHA 2021 episode of Parallax, Dr Ankur Kalra\u2019s guest is Dr Amit Khera, Professor and Director of Preventive Cardiology at UT Southwestern Medical Center, Dallas and Vice Chair of the Scientific Sessions.\n\nFor this week\u2019s show, Dr Khera selected three thought-provoking late-breaking trials that will inform or change clinical practice. Ankur and Amit discuss how the AVATAR trial will influence guidelines, and whether these findings could be translated to TAVR. Most importantly, they discuss how AVATAR\u2019s results could inform patient decisions.\nNext, Dr Khera highlights a randomized trial that was designed to address the needs of a larger population. The China Rural Hypertension Control Project offers exciting insights and an innovative framework for relying on social healthcare work.\nLastly, Dr Kalra and Dr Khera discuss a trial that investigated the LDL-cholesterol lowering efficacy of MK-0616. This oral PCSK9 Inhibitor may open the door for more patients in the future.\n\nWhat were the key findings? What are the take-home messages? How will these 3 trials foster new opportunities for patients?\n\nTrials covered in detail include:\n\u2022 Aortic Valve Replacement versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial\n\u2022 A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project\n\u2022 The Clinical Safety, Pharmacokinetics, and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor\n\nQuestions and comments can be sent to \u201cpodcast@radcliffe-group.com\u201d and may be answered by Ankur in the next episode. Guest @dramitkhera hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.\n\nBrought to you by Edwards: www.edwardstavr.com